The BioHub: The Top Voices in Biotech Episode 134 - Amit Etkin - Founder & CEO Alto Neuroscience
Mar 20, 2026
Amit Etkin, MD, PhD, psychiatrist and neuroscientist who founded Alto Neuroscience to bring precision medicine to mental health. He narrates his move from academia to building a biomarker-driven company. Conversations cover why CNS drug development struggles, Alto’s data-first strategy and portfolio thinking, and bold plans to reshape treatments for depression and cognitive deficits in schizophrenia.
AI Snips
Chapters
Transcript
Episode notes
Leaving Tenure For Real-World Impact
- Amit Etkin left a tenured Stanford professorship to start Alto because his lab findings reached a point where real-world impact required building products and treatments.
- He called this the "last paragraph effect" where papers' future-aiming conclusions pushed him to translate reproducible biomarkers into clinical tools.
Why Building Drugs Gave Alto More Leverage
- Alto began with three precision psychiatry pillars: optimize existing care, partner with pharma, and develop internal drugs, but found drug development gave the most control.
- Focusing on internal drug development lets Alto systematically bring new mechanisms to patients and create generalized precision approaches.
Use Data Gates And Urgency To Guide Decisions
- Rethink everything and let data decide: embed go/no-go gates and replication checks across projects to prevent optimism and confirmation bias.
- Pair that with operating with urgency so decisions are evidence-led but executed fast toward patient impact.